New drug cocktail aims to boost lung cancer treatment
NCT ID NCT03991819
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. The study includes 40 participants whose tumors have high PD-L1 levels. Researchers are looking at safety, the best dose, and how many tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- binimetinib and pembrolizumab (Keytruda)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels.
- What could go wrong
- This is an early Phase I trial with only 40 participants, so results are preliminary. The combination may cause side effects or not work better than pembrolizumab alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z5, Canada
-
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers
- Experimental drug targets Hard-to-Treat cancers, but trial ends early
- Liver zapping may supercharge lung cancer treatment
- Step up recovery: telecoaching aims to boost activity after lung cancer surgery
- Triple drug cocktail targets tough lung cancer
- New hope for advanced lung cancer: experimental drug takes on chemo in major trial